Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 7 participants, all of whom received a treatment called ranibizumab (given as an injection into the eye) for a condition called macular oedema — a swelling at the centre of the retina that can affect vision. Six of the seven participants completed the trial; one did not finish. The trial was measuring changes in vision sharpness and retinal thickness over time, as well as counting any unwanted events that occurred. The reported data shows that, on average, participants' best corrected vision (that is, vision measured with the most suitable glasses or lenses in place, using a standardised letter chart) improved by 13 letters from the starting point to the 3-month mark. When looking at the longer period from 6 to 12 months, the reported median change (the middle value across participants) in vision was a decrease of 2 letters. The reported data also shows changes in the thickness of the central retina, measured in microns (millionths of a metre): the thickness decreased by 267 microns at 7 days, 356 microns at 3 months, 354 microns at 6 months, 243 microns at 9 months, and 388 microns at 12 months — all reductions from the starting measurement. The reported data shows that zero episodes of a specific type of eye inflammation (called a uveitis flare, meaning significant inflammation inside the eye) were recorded. Four unwanted events — covering both eye-related and non-eye-related occurrences — were reported in total, though a breakdown of what those events were is not provided in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are able to give written consent and are willing to take part in all study visits and assessments for the full length of the study
- You are 18 years of age or older
- You have a history of uveitis (eye inflammation) that is not caused by infection, and you have had fluid swelling in the central part of your retina (called cystoid macular edema) for more than 3 months
- A special eye scan (OCT) shows that the swelling in the central part of your retina measures 300 µM or more
- You have previously tried steroid treatment (either as pills or injections) for at least 30 days, but the swelling in your retina has not gone away — or you are unable to use steroid injections because they have previously caused your eye pressure to rise too high
- The level of inflammation inside your eye is very low (at "trace" level or below, based on a standard medical scale)
- Your vision in the eye being studied is between 20/40 and 20/400 on a standard eye chart
- Your eye is clear enough, your pupil can be dilated, and you are able to cooperate enough to allow eye scanning and retinal photography
Who may not be able to join:
- You are pregnant, have tested positive for pregnancy, or are of childbearing age and are not using adequate birth control
- You have received steroid treatment (pills or injections), or certain eye injections (Macugen or Avastin) for your retinal swelling within the 6 weeks before joining the study
- You have previously had a vitrectomy (a type of eye surgery to remove the gel inside the eye)
- You currently have significant active inflammation inside the eye being studied (more than "trace" level)
- You currently have bleeding inside the eye
- You have an active eye infection (such as in the surface of the eye or inner eye) in either eye
- You have a known allergy to any ingredient in the study drug
- Your eye pressure is above 30 mmHg even while using glaucoma medications
- Your blood pressure is above 180/110 — though if medication brings it below this level, you may become eligible
- You have major surgery planned within the next 6 months
- You have any other health condition that the study doctor believes could put you at significant risk if you took the study drug (confirm with trial site)
- You are currently taking part in another medical study or clinical trial
- You are unwilling or unable to follow all study-related procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Mean Change at 3 Months in BSCVA From Baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.